Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ndonovo Therapeutics Inc (ENDV)

Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
Endonovo Therapeutics, Inc. is a biotechnology company which is engaged in developing a bioelectronic approach to regenerative medicine. The company's Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics(TM) platform provides method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies. Endonovo Therapeutics, Inc. is headquartered in Woodland Hills, California.

Fiscal Year End Date: 12/31

(Values in U.S. Thousands) Dec, 2024 Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020
Sales 10 140 140 70 170
Sales Growth -92.86% unch +100.00% -58.82% -45.16%
Net Income -2,800 6,920 -18,470 -3,100 -400
Net Income Growth -140.46% +137.47% -495.81% -675.00% +97.69%
(Values in U.S. Thousands) Dec, 2024 Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020
Total Assets 640 1,280 2,010 2,610 3,270
Total Assets Growth -50.00% -36.32% -22.99% -20.18% -22.88%
Total Liabilities 24,750 33,460 17,780 16,980 23,780
Total Liabilities Growth -26.03% +88.19% +4.71% -28.60% +52.14%
(Values in U.S. Thousands) Dec, 2024 Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020
Operating Cash Flow 120 -680 -990 -740 -2,540
Operating Cash Flow Growth +117.65% +31.31% -33.78% +70.87% +11.81%
Net Cash Flow 0 -90 70 -10 -360
Change in Net Cash Flow +100.00% -228.57% +800.08% +97.22% -224.14%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar